TGTX PE Ratio & Valuation,Is TGTX Overvalued

TGTX Relative Valuation

TGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TGTX is overvalued; if below, it's undervalued.

Historical Valuation

TG Therapeutics Inc (TGTX) is now in the Fair zone, suggesting that its current forward PS ratio of 5.55 is considered Fairly compared with the five-year average of 21.36. The fair price of TG Therapeutics Inc (TGTX) is between 30.80 to 46.30 according to relative valuation methord.

Relative Value

Fair Zone

30.80-46.30

Current Price：31.35

Fair

21.65

17.21

EV/EBITDA

TG Therapeutics Inc. (TGTX) has a current EV/EBITDA of 17.21. The 5-year average EV/EBITDA is -9.84. The thresholds are as follows: Strongly Undervalued below -183.59, Undervalued between -183.59 and -96.72, Fairly Valued between 77.03 and -96.72, Overvalued between 77.03 and 163.91, and Strongly Overvalued above 163.91. The current Forward EV/EBITDA of 17.21 falls within the Historic Trend Line -Fairly Valued range.

17.25

EV/EBIT

TG Therapeutics Inc. (TGTX) has a current EV/EBIT of 17.25. The 5-year average EV/EBIT is 13.58. The thresholds are as follows: Strongly Undervalued below -80.84, Undervalued between -80.84 and -33.63, Fairly Valued between 60.79 and -33.63, Overvalued between 60.79 and 108.00, and Strongly Overvalued above 108.00. The current Forward EV/EBIT of 17.25 falls within the Historic Trend Line -Fairly Valued range.

5.55

TG Therapeutics Inc. (TGTX) has a current PS of 5.55. The 5-year average PS is 96.36. The thresholds are as follows: Strongly Undervalued below -308.39, Undervalued between -308.39 and -106.01, Fairly Valued between 298.74 and -106.01, Overvalued between 298.74 and 501.11, and Strongly Overvalued above 501.11. The current Forward PS of 5.55 falls within the Historic Trend Line -Fairly Valued range.

11.06

P/OCF

TG Therapeutics Inc. (TGTX) has a current P/OCF of 11.06. The 5-year average P/OCF is 26.73. The thresholds are as follows: Strongly Undervalued below -341.46, Undervalued between -341.46 and -157.36, Fairly Valued between 210.83 and -157.36, Overvalued between 210.83 and 394.93, and Strongly Overvalued above 394.93. The current Forward P/OCF of 11.06 falls within the Historic Trend Line -Fairly Valued range.

13.23

P/FCF

TG Therapeutics Inc. (TGTX) has a current P/FCF of 13.23. The 5-year average P/FCF is 28.77. The thresholds are as follows: Strongly Undervalued below -231.70, Undervalued between -231.70 and -101.47, Fairly Valued between 159.01 and -101.47, Overvalued between 159.01 and 289.25, and Strongly Overvalued above 289.25. The current Forward P/FCF of 13.23 falls within the Historic Trend Line -Fairly Valued range.

TG Therapeutics Inc (TGTX) has a current Price-to-Book (P/B) ratio of 7.37. Compared to its 3-year average P/B ratio of 30.46 , the current P/B ratio is approximately -75.81% higher. Relative to its 5-year average P/B ratio of 22.04, the current P/B ratio is about -66.58% higher. TG Therapeutics Inc (TGTX) has a Forward Free Cash Flow (FCF) yield of approximately -1.53%. Compared to its 3-year average FCF yield of -2.62%, the current FCF yield is approximately -41.53% lower. Relative to its 5-year average FCF yield of -8.37% , the current FCF yield is about -81.70% lower.

7.37

P/B

Median3y

30.46

Median5y

22.04

-1.53

FCF Yield

Median3y

-2.62

Median5y

-8.37

Competitors Valuation Multiple

The average P/S ratio for TGTX's competitors is 30.42, providing a benchmark for relative valuation. TG Therapeutics Inc Corp (TGTX) exhibits a P/S ratio of 5.55, which is -81.77% above the industry average. Given its robust revenue growth of 92.79%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TGTX increased by 4.15% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 4.63 to 241.73.

The secondary factor is the Revenue Growth, contributed 92.79%to the performance.

Overall, the performance of TGTX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

92.79%

83.88M → 161.71M

Revenue Growth

5120.95%

4.63 → 241.73

Margin Expansion

-5209.59%

-0.22 → 11.29

P/E Change

4.15%

30.10 → 31.35

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is TG Therapeutics Inc (TGTX) currently overvalued or undervalued?

What is TG Therapeutics Inc (TGTX) fair value?

TGTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of TG Therapeutics Inc (TGTX) is between 30.80 to 46.30 according to relative valuation methord.

How does TGTX's valuation metrics compare to the industry average?

What is the current P/B ratio for TG Therapeutics Inc (TGTX) as of Dec 15 2025?

As of Dec 15 2025, TG Therapeutics Inc (TGTX) has a P/B ratio of 7.37. This indicates that the market values TGTX at 7.37 times its book value.

What is the current FCF Yield for TG Therapeutics Inc (TGTX) as of Dec 15 2025?

As of Dec 15 2025, TG Therapeutics Inc (TGTX) has a FCF Yield of -1.53%. This means that for every dollar of TG Therapeutics Inc’s market capitalization, the company generates -1.53 cents in free cash flow.

What is the current Forward P/E ratio for TG Therapeutics Inc (TGTX) as of Dec 15 2025?

As of Dec 15 2025, TG Therapeutics Inc (TGTX) has a Forward P/E ratio of 21.65. This means the market is willing to pay $21.65 for every dollar of TG Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for TG Therapeutics Inc (TGTX) as of Dec 15 2025?

As of Dec 15 2025, TG Therapeutics Inc (TGTX) has a Forward P/S ratio of 5.55. This means the market is valuing TGTX at $5.55 for every dollar of expected revenue over the next 12 months.

TGTX Valuation